Logo image of PRE

PRENETICS GLOBAL LTD-CL A (PRE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRE - KYG722451229 - Common Stock

12.68 USD
-0.2 (-1.55%)
Last: 11/21/2025, 8:00:01 PM
12.68 USD
0 (0%)
After Hours: 11/21/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PRE. PRE was compared to 101 industry peers in the Health Care Providers & Services industry. While PRE seems to be doing ok healthwise, there are quite some concerns on its profitability. PRE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year PRE has reported negative net income.
PRE had negative earnings in each of the past 5 years.
PRE had negative operating cash flow in 4 of the past 5 years.
PRE Yearly Net Income VS EBIT VS OCF VS FCFPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

PRE has a worse Return On Assets (-25.50%) than 81.19% of its industry peers.
PRE has a Return On Equity of -31.41%. This is in the lower half of the industry: PRE underperforms 68.32% of its industry peers.
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
PRE Yearly ROA, ROE, ROICPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

PRE has a better Gross Margin (42.48%) than 70.30% of its industry peers.
PRE's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for PRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
PRE Yearly Profit, Operating, Gross MarginsPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200

6

2. Health

2.1 Basic Checks

PRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRE has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, PRE has an improved debt to assets ratio.
PRE Yearly Shares OutstandingPRE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
PRE Yearly Total Debt VS Total AssetsPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

PRE has an Altman-Z score of 2.96. This is not the best score and indicates that PRE is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.96, PRE is in the better half of the industry, outperforming 63.37% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that PRE is not too dependend on debt financing.
PRE's Debt to Equity ratio of 0.00 is amongst the best of the industry. PRE outperforms 85.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.96
ROIC/WACCN/A
WACC8.27%
PRE Yearly LT Debt VS Equity VS FCFPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.37 indicates that PRE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.37, PRE belongs to the top of the industry, outperforming 82.18% of the companies in the same industry.
PRE has a Quick Ratio of 2.29. This indicates that PRE is financially healthy and has no problem in meeting its short term obligations.
PRE has a Quick ratio of 2.29. This is amongst the best in the industry. PRE outperforms 82.18% of its industry peers.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.29
PRE Yearly Current Assets VS Current LiabilitesPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

4

3. Growth

3.1 Past

PRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.17%, which is quite impressive.
Looking at the last year, PRE shows a very negative growth in Revenue. The Revenue has decreased by -92.12% in the last year.
Measured over the past years, PRE shows a very negative growth in Revenue. The Revenue has been decreasing by -30.65% on average per year.
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.9%
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%202.88%

3.2 Future

PRE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.61% yearly.
The Revenue is expected to grow by 34.15% on average over the next years. This is a very strong growth
EPS Next Y20.64%
EPS Next 2Y17.66%
EPS Next 3Y25.69%
EPS Next 5Y22.61%
Revenue Next Year-56.61%
Revenue Next 2Y10.48%
Revenue Next 3Y35.45%
Revenue Next 5Y34.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PRE Yearly Revenue VS EstimatesPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
PRE Yearly EPS VS EstimatesPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRE Price Earnings VS Forward Price EarningsPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRE Per share dataPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PRE's earnings are expected to grow with 25.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.66%
EPS Next 3Y25.69%

0

5. Dividend

5.1 Amount

No dividends for PRE!.
Industry RankSector Rank
Dividend Yield N/A

PRENETICS GLOBAL LTD-CL A

NASDAQ:PRE (11/21/2025, 8:00:01 PM)

After market: 12.68 0 (0%)

12.68

-0.2 (-1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners10.13%
Inst Owner Change12.21%
Ins Owners14.52%
Ins Owner Change0%
Market Cap165.22M
Revenue(TTM)21.74M
Net Income(TTM)-64.82M
Analysts80
Price Target31.62 (149.37%)
Short Float %1.82%
Short Ratio1.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.43%
Min EPS beat(2)-107.26%
Max EPS beat(2)90.4%
EPS beat(4)1
Avg EPS beat(4)-32.6%
Min EPS beat(4)-107.26%
Max EPS beat(4)90.4%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-71.46%
Min Revenue beat(2)-73.45%
Max Revenue beat(2)-69.46%
Revenue beat(4)0
Avg Revenue beat(4)-62.2%
Min Revenue beat(4)-78.3%
Max Revenue beat(4)-27.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.23%
PT rev (3m)121.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.9
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-3.55
EYN/A
EPS(NY)-2.59
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.59
BVpS15.84
TBVpS12.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.48%
FCFM N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.29
Altman-Z 2.96
F-ScoreN/A
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.9%
EPS Next Y20.64%
EPS Next 2Y17.66%
EPS Next 3Y25.69%
EPS Next 5Y22.61%
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%202.88%
Revenue Next Year-56.61%
Revenue Next 2Y10.48%
Revenue Next 3Y35.45%
Revenue Next 5Y34.15%
EBIT growth 1Y-19586.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

PRENETICS GLOBAL LTD-CL A / PRE FAQ

What is the ChartMill fundamental rating of PRENETICS GLOBAL LTD-CL A (PRE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRE.


Can you provide the valuation status for PRENETICS GLOBAL LTD-CL A?

ChartMill assigns a valuation rating of 1 / 10 to PRENETICS GLOBAL LTD-CL A (PRE). This can be considered as Overvalued.


Can you provide the profitability details for PRENETICS GLOBAL LTD-CL A?

PRENETICS GLOBAL LTD-CL A (PRE) has a profitability rating of 1 / 10.


Can you provide the financial health for PRE stock?

The financial health rating of PRENETICS GLOBAL LTD-CL A (PRE) is 6 / 10.